iBIO https://ibio.org To promote, connect and engage the life sciences community Fri, 11 Oct 2019 11:42:38 +0000 en-US hourly 1 Promoting Empowerment on International Day of the Girl https://ibio.org/promoting-empowerment-on-international-day-of-the-girl/ https://ibio.org/promoting-empowerment-on-international-day-of-the-girl/#respond Fri, 11 Oct 2019 11:27:09 +0000 https://ibio.org/?p=4383

Friday, October 11 marks the seventh “International Day of the Girl”. The day seeks to highlight the needs and specific challenges girls face and promote girls’ empowerment and the fulfillment of their human rights.

You might now be thinking, it’s 2019, is this really necessary? The answer is perhaps best summarized by Melinda Gates in her recent article: Here’s Why I’m Committing $1 Billion to Promote Gender Equality[1]. Gates writes,In 2018, there were more men named James running Fortune 500 companies than there were women. This year, only one CEO on that list of 500 is a woman of color.”

Today, iBIO celebrates the International Day of the Girl. And we commit to helping girls grades 3-8 discover and embrace their interests, self-confidence and skills in STEM.

We invite you to celebrate with us and help us strengthen and expand Stellar Girls and STEMgirls, our programs for girls grades 3-8 which provide after-school and summer camp opportunities to explore STEM. Girls are empowered by these programs. Through fun, hands-on STEM and STEAM-centered activities, girls develop a belief in their own abilities that will persist and withstand the many obstacles to achieving their goals. They build and test their own windmill designs, design and build working flashlights and recycling sorter conveyor belts. They make ice cream to learn about chemistry and explore antigens and antibodies. Through these and dozens of other activities, girls learn about themselves as much as they learn STEM concepts. They learn that, in STEM, “failure” is actually a healthy and necessary part of creating a more enduring success.

We invite you to join us in celebrating young women and commit yourself to volunteering for these important programs. Our volunteers give girls visibility to women and men working in STEM careers, help girls recognize their own potential, and make connections between the hands-on explorations and future careers. If you are interested in volunteering please contact ann.vogel@ibioinstitute.org.

Support iBIO’s STEM programs that inspire and empower the next generation of life sciences leaders

 

[1] https://time.com/5690596/melinda-gates-empowering-women/

]]>
https://ibio.org/promoting-empowerment-on-international-day-of-the-girl/feed/ 0
Governor Pritzker Names Life Sciences Industry as Key Pillar of Illinois Strategic Plan https://ibio.org/the-life-sciences-industry-is-a-key-pillar-of-illinois-strategic-plan/ https://ibio.org/the-life-sciences-industry-is-a-key-pillar-of-illinois-strategic-plan/#respond Wed, 09 Oct 2019 17:57:31 +0000 https://ibio.org/?p=4375 iBIO Commends Governor Pritzker and the Illinois Department of Commerce and Economic Opportunity (DCEO) for making life sciences industry one of the key pillars in the state’s 5-year blueprint for jobs. Earlier today Governor Pritzker and Illinois DCEO Director Erin Guthrie announced the release of DCEO’s 5 year plan: A Plan to Revitalize the Illinois Economy and Build the Workforce of the Future.

The plan focuses on some of the key challenges outlined in iBIO’s 2019 State of the Industry. Notably the plan identifies the life sciences industry as one of the key pillars and includes a number of provisions to support economic growth:

  • Invest in facilities that encourage collaboration between researchers, industry
  • Give startups access to the R&D Tax Credit
  • Work with Industry to identify regulatory hurdles
  • Build wet lab space & provide tax incentives for the private development of wet lab space
  • Work with the community college board and industry stakeholders to address workforce issues
  • Work with the Illinois Treasurer’s office to prioritize life sciences and biopharma investment
  • Update and fund an SBIR Matching program in Illinois, one of iBIO’s key legislative priorities from this past year

Over the past year, iBIO has worked closely with the Governor’s office and DCEO to raise awareness on some of these issues. We look forward to continuing to work with the state to address some of our major challenges and grow the life sciences industry in Illinois.

Thank you to Governor Pritzker, and Illinois DCEO Director Erin Guthrie for your leadership.

You can read the full report here: A Plan to Revitalize the Illinois Economy and Build the Workforce of the Future

]]>
https://ibio.org/the-life-sciences-industry-is-a-key-pillar-of-illinois-strategic-plan/feed/ 0
Tell Congress Doctors, Not Bureaucrats, Should Decide What Medicines Americans Receive https://ibio.org/tell-congress-doctors-not-bureaucrats-should-decide-what-medicines-americans-receive/ https://ibio.org/tell-congress-doctors-not-bureaucrats-should-decide-what-medicines-americans-receive/#respond Wed, 02 Oct 2019 16:20:05 +0000 https://ibio.org/?p=4337 Policymakers in Washington are debating reforms they claim will lower prescription drug prices. It’s important our elected leaders offer real solutions instead of partisan soundbites that mask the real harm to patients by their government-run scheme.

The House of Representatives is expected to soon vote on a bill (H.R. 3) that would let the government come between patients and the treatments and medicines they need. The legislation would adopt health care policies set by foreign countries that lead to rationed care and restricted access to prescription medicines.

This extreme bill will upend the Medicare program for more than 50 million seniors and impose a government-run drug pricing scheme on workers and families with private health care. H.R. 3 will save money for the government and insurance companies, but it will reduce the quality of care for many Americans and do almost nothing to lower patients’ out-of-pocket drug costs. 

Congress will continue debating drug pricing legislation in the coming weeks. Make your voice heard today!

Email your elected officials and tell them to oppose H.R. 3. Let them know that doctors – not bureaucrats – should decide which medicines America’s patients can receive. Urge your elected leaders to reject H.R. 3 and support responsible solutions that lower what people pay out of pocket for prescription medicines and ensure all patients can get the cures and treatments they need.

 

ACT NOW!

 

iBIO Opposes New Drug Pricing Bill from House Democrats Leadership

iBIO is very concerned with the provisions included in H.R.3 to establish price controls as a mechanism for lowering list prices for pharmaceuticals in the US.

Specifically H.R. 3 would:

  • Require the Secretary of Health and Human Services (HHS) to directly negotiate the price of 25 to 250 brand-name drugs annually that lack a generic or biosimilar competitor and have the greatest cost to Medicare and the U.S. health system. H.R. 3 would establish an upper limit for the price reached in any negotiation as no more than 120 percent of the volume-weighted average of the price of six countries (Australia, Canada, France, Germany, Japan, and the United Kingdom). This price is known as the Average International Market (AIM) price. The articulated goal of this policy is for HHS to negotiate a price that is below the AIM, called the “maximum fair price”, which would be applied to Medicare. Medicare Advantage and Part D plans could use additional tools to negotiate even lower prices.
  • Require a manufacturer to offer the maximum price set by HHS to the commercial market. If a manufacturer does not agree with the maximum price, they will be assessed a penalty starting at 65% of the annual gross sales and increasing 10% every quarter to a maximum of 95%. If the manufacturer agrees to the maximum price, but overcharges Medicare or fails to offer the price to other payers, they are subject to a civil monetary penalty of 10 times the difference between the price charged and the maximum price. The bill would also establish a new inflation rebate for the more than 8,000 drugs in Medicare Parts B and D, retroactive to 2016, and the drug company can either lower the price or rebate the entire amount above inflation to the Treasury.
  • Create a $2,000 out-of-pocket limit on Medicare Part D beneficiary prescription drug costs, beginning in 2022, and redesigns the program to have an initial coverage period and then catastrophic phase, effectively eliminating the coverage gap. However, the bill lowers the government’s exposure in the catastrophic phase from 80% to 20%, increases the insurers exposure from 20% to 50%, and increases manufacturer exposure from zero to 30%. Manufacturers would also be required to pay 10% in the initial coverage period. (Notably, this is a significant increase from the bipartisan Senate Finance Committee proposal, which would eliminate the coverage gap and have manufacturers pay 20% in the catastrophic phase.)

Read more about iBIO’s concerns with H.R.3

]]>
https://ibio.org/tell-congress-doctors-not-bureaucrats-should-decide-what-medicines-americans-receive/feed/ 0
iBIO Honors Life Sciences Educators, Innovators and Entrepreneurs at the 13th Annual ICON Awards https://ibio.org/ibio-honors-life-sciences-educators-innovators-and-entrepreneurs-at-the-13th-annual-icon-awards/ https://ibio.org/ibio-honors-life-sciences-educators-innovators-and-entrepreneurs-at-the-13th-annual-icon-awards/#respond Tue, 01 Oct 2019 15:42:22 +0000 https://ibio.org/?p=4323 The Illinois Biotechnology Innovation Organization (iBIO) hosted the thirteenth annual iCON awards last night at The Chicago Botanic Garden.

The night brought members of the life sciences community together to celebrate the accomplishments of outstanding innovators and leaders whose work provides the basis for life sciences developments worldwide. Funds raised at the iCON Awards ceremony supports the mission of iBIO’s EDUCATE Programs, a 501(c)3 public charity, which orchestrates business leadership in delivery of world-class educational after-school programs and summer STEM camps for girls grades 3-8 in underserved Illinois schools.

“Each year we are proud to support the work of trailblazing life sciences innovators and educators in Illinois,” said John Conrad, president and CEO of iBIO. “Funds raised will allow us to continue to provide STEM learning opportunities to students and teachers across the state in support the next generation of life science innovators here in Illinois.”

The 2019 iCON Entrepreneurial Award, which recognizes a pioneering entrepreneur who is a risk taker and visionary leader, was presented to Paul Edick, Chairman and CEO of Xeris, a public specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.

Edick joined Xeris Pharmaceuticals as Chairman and Chief Executive Officer in January 2017.  Prior to joining Xeris, Edick was a Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. In addition, he served as the Chief Executive Officer of Durata Therapeutics from 2010-2014 and has held the post of CEO at a number of other pharmaceutical companies, including Ganic Pharmaceuticals and MedPointe Healthcare, Inc. Edick currently serves as the Chairman of the Board of Milestone Pharmaceuticals Inc. Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards, including Interim Therapeutics, PDL, BioPharma, Neos Therapeutics, NewLink Genetics Inc., Circassia Pharmaceuticals plc, Sucampo Pharmaceuticals, Amerita Inc., and Informed Medical Communications.

The 2019 iCON Innovator Award, which recognizes scientists who demonstrate leadership potential at the frontier of knowledge in the life sciences and conduct research that is anticipated to enhance economic development in the State of Illinois, was presented to Dr. Martin Burke, a professor in the Department of Chemistry at the University of Illinois Urbana-Champaign and the Associate Dean for Research at the Carle Illinois College of Medicine. 

Dr. Burke’s group has pioneered the field of molecular prosthetics, including the development of an automated Lego-like platform for democratizing small molecule synthesis. Dr. Burke has received a number of honors and awards, including the Nobel Laureate Signature Award for Graduate Education in Chemistry from the American Chemical Society and has garnered praise for excellence in teaching at both the undergraduate and graduate levels. Dr. Burke is also the founder of four biotechnology companies: REVOLUTION Medicines, Ambys Medicines, Sfunga Therapeutics and Cystetic Medicines. 

The iCON Knowledge Builder Award, which recognizes educators who demonstrate exemplary teaching at the grade 6-12 level, and who have positively impacted students’ understanding of biotechnology’s promise and challenges, was presented to Rebecca Voight, a teacher at Andrew Cooke Magnet Elementary School in Waukegan, Illinois.

Voight is a member of the Instructional Leadership Team and has led the school’s engagement with the StellarGirls program for the past three years. Voight has a Masters of Education in Curriculum from Lesly University in Cambridge, Massachusetts and a B.A. in Elementary Education from Northern Illinois University. 

 

]]>
https://ibio.org/ibio-honors-life-sciences-educators-innovators-and-entrepreneurs-at-the-13th-annual-icon-awards/feed/ 0
iBIO Opposes New Drug Pricing Bill from House Democrats Leadership https://ibio.org/ibio-opposes-new-drug-pricing-bill-from-house-democrats-leadership/ https://ibio.org/ibio-opposes-new-drug-pricing-bill-from-house-democrats-leadership/#respond Fri, 27 Sep 2019 11:11:56 +0000 https://ibio.org/?p=4316 On Sept. 19, House Speaker Nancy Pelosi (D-San Francisco) unveiled legislation in the form of the Lower Drug Costs Now Act (H.R. 3)

Illinois is home to over 45,000 researchers, doctors, lawyers and business women and men in the biopharma industry who have an unwavering commitment to improving patient lives.

iBIO’s members are committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed medications to patients. Our members believe that all patients who can benefit from medications and therapies should have access to them.

iBIO is very concerned with the provisions included in H.R.3 to establish price controls as a mechanism for lowering list prices for pharmaceuticals in the US.

Specifically H.R. 3 would:

  • Require the Secretary of Health and Human Services (HHS) to directly negotiate the price of 25 to 250 brand-name drugs annually that lack a generic or biosimilar competitor and have the greatest cost to Medicare and the U.S. health system. H.R. 3 would establish an upper limit for the price reached in any negotiation as no more than 120 percent of the volume-weighted average of the price of six countries (Australia, Canada, France, Germany, Japan, and the United Kingdom). This price is known as the Average International Market (AIM) price. The articulated goal of this policy is for HHS to negotiate a price that is below the AIM, called the “maximum fair price”, which would be applied to Medicare. Medicare Advantage and Part D plans could use additional tools to negotiate even lower prices.
  • Require a manufacturer to offer the maximum price set by HHS to the commercial market. If a manufacturer does not agree with the maximum price, they will be assessed a penalty starting at 65% of the annual gross sales and increasing 10% every quarter to a maximum of 95%. If the manufacturer agrees to the maximum price, but overcharges Medicare or fails to offer the price to other payers, they are subject to a civil monetary penalty of 10 times the difference between the price charged and the maximum price. The bill would also establish a new inflation rebate for the more than 8,000 drugs in Medicare Parts B and D, retroactive to 2016, and the drug company can either lower the price or rebate the entire amount above inflation to the Treasury.
  • Create a $2,000 out-of-pocket limit on Medicare Part D beneficiary prescription drug costs, beginning in 2022, and redesigns the program to have an initial coverage period and then catastrophic phase, effectively eliminating the coverage gap. However, the bill lowers the government’s exposure in the catastrophic phase from 80% to 20%, increases the insurers exposure from 20% to 50%, and increases manufacturer exposure from zero to 30%. Manufacturers would also be required to pay 10% in the initial coverage period. (Notably, this is a significant increase from the bipartisan Senate Finance Committee proposal, which would eliminate the coverage gap and have manufacturers pay 20% in the catastrophic phase.)

iBIO is opposed to any provision to transform Medicare Part B from a market-based payment formula to one tied to imported price controls. Understanding how prices vary between nations requires a comprehensive understanding of the different market access systems that exist for prescription drugs. These plans do not take into consideration the impact on patients and their access to life saving therapeutics.

What is of more concern is the cooling effect H.R. 3 could have on venture investment for small and emerging companies. More than 90% of the Biopharmaceutical industry is made up of small and emerging companies. These companies are responsible for 70% of the global clinical pipeline. This part of the industry is not actively engaged in the sale of pharmaceuticals or setting drug prices, but the impact of H.R. 3 for these companies can be great.

iBIO will work with our national partners to oppose the provisions in H.R. 3.

 

ACT NOW!

 

More resources on this issue:

International Drug Pricing – HOUSE 9-25-19 FINAL

pelosi high level summary sept 19

]]>
https://ibio.org/ibio-opposes-new-drug-pricing-bill-from-house-democrats-leadership/feed/ 0
Op-ed: Illinois is running out of lab space https://ibio.org/op-ed-illinois-is-running-out-of-lab-space/ https://ibio.org/op-ed-illinois-is-running-out-of-lab-space/#respond Thu, 26 Sep 2019 11:32:46 +0000 https://ibio.org/?p=4311 This Oped was originally published in Crain’s Chicago Business on September 6, 2019

John Pletz’s article (“Will these startups help biotech take root in Chicago?” Aug. 9) highlights a shift in the Illinois biotech community and underscores the need to realign Illinois resources to help biotech take root in Illinois.

Illinois has always been home to world-class researchers like the University of Chicago’s Dr. Tom Gajewski, but in the past five years, we have seen the universities align investment and resources to increase the number of startups coming out of those researchers’ labs. Just this year we have seen Illinois universities partner with groups like Deerfield Management to provide translational research funding, which will continue to fuel the creation of startup companies in our community. And we have seen recent trends of former executives from large pharma and biotech companies successfully building startups and attracting talent to Illinois. Companies like Xeris, Aptinyx and AveXis are helping Illinois change the narrative.

But John Flavin and David Steinberg are correct in the article: Our community does not have the infrastructure to support these startups. According to CBRE’s “2019 U.S. Life Sciences Clusters” report, metro Chicago has 2.966 million square feet of lab space with almost no vacancy. If you add the expansion at the Illinois Science + Technology Park, Sterling Bay’s 2430 N. Halsted building and Rosalind Franklin University’s Innovation & Research Park, that brings the total lab space to just over 3.3 million square feet. By comparison, Boston-Cambridge currently has 28 million square feet of lab space with an additional 1.87 million square feet under construction. Raleigh-Durham has 5 million square feet of lab space, including sites under construction.

For emerging biotech startups in Illinois, the availability of quality laboratory space is one of the most crucial components for continued growth, innovation and development, and yet it is one of Illinois’ scarcest resources. To support the growth of our community, resources need to be realigned to increase investment into infrastructure expansions because expanding the biotech industry in Illinois doesn’t just mean more jobs, it also helps people live longer and healthier lives.

 

]]>
https://ibio.org/op-ed-illinois-is-running-out-of-lab-space/feed/ 0
The 2019 iCON Awards are Tomorrow! https://ibio.org/the-2019-icon-awards-are-tomorrow/ https://ibio.org/the-2019-icon-awards-are-tomorrow/#respond Wed, 25 Sep 2019 12:18:46 +0000 https://ibio.org/?p=4307

2019 iCON Awards
September 26, 2019 – Chicago Botanic Garden

The 2019 iCON Awards are tomorrow! It’s not too late to register. 

The iCON Awards celebrate the accomplishments of outstanding innovators and leaders whose work provides the basis for life sciences developments worldwide. Visit iBIO’s websiteto learn more about tickets and sponsorships opportunities available now.

Funds raised at the iCON Awards ceremony further the mission of iBIO’s nationally-recognized EDUCATE charitable programs which orchestrates business leadership in delivery of world-class educational after-school programs and summer STEM camps for girls grades 3-8 in underserved Illinois schools.

Paul Edick, Chairman & CEO, Xeris Pharmaceuticals

Paul Edick, Chairman & CEO, Xeris Pharmaceuticals

2019 iCON Award Winner

Mr. Edick joined Xeris Pharmaceuticals as Chairman and Chief Executive Officer in January 2017. Prior to joining Xeris, Edick was a Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. In addition, Mr. Edick served as the Chief Executive Officer of Durata Therapeutics from 2010-2014 and has held the post of CEO at a number of other pharmaceutical companies, including Ganic Pharmaceuticals and MedPointe Healthcare, Inc. Mr. Edick currently serves as the Chairman of the Board of Milestone Pharmaceuticals Inc. Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards, including Interim Therapeutics, PDL, BioPharma, Neos Therapeutics, NewLink Genetics Inc., Circassia Pharmaceuticals plc, Sucampo Pharmaceuticals, Amerita Inc., and Informed Medical Communications.

Dr. Martin D. Burke, University of Illinois

Dr. Martin D. Burke, University of Illinois

2019 iCON Innovator Award

Dr. Burke’s group has pioneered the field of molecular prosthetics, including the development of an automated Lego-like platform for democratizing small molecule synthesis. Dr. Burke has received a number of honors and awards, including the Nobel Laureate Signature Award for Graduate Education in Chemistry from the American Chemical Society and has garnered praise for excellence in teaching at both the undergraduate and graduate levels. Dr. Burke is also the founder of four biotechnology companies: REVOLUTION Medicines, Ambys Medicines, Sfunga Therapeutics and Cystetic Medicines.

Rebecca Voight, Cooke Magnet Elementary School, IL

Rebecca Voight, Cooke Magnet Elementary School, IL

2019 iCON Knowledge Builder Award

Rebecca Voight is a teacher at the Andrew Magnet Elementary School in Waukegan Illinois where Ms Voight is a member of the Instructional Leadership Team and has led the school’s engagement with the STEMGirls Camp program for the past three years.

Tickets/table registrations and sponsorship opportunities are now available. Funds raised at the iCON Awards ceremony supports the mission of iBIO’s EDUCATE Programs, a 501(c)3 public charity, which orchestrates business leadership in delivery of world-class educational after-school programs and summer STEM camps for girls grades 3-8 in underserved Illinois schools.

THANK YOU FOR YOUR CONTINUED SUPPORT

The iCON Awards Dinner have been supported by our community’s leading organizations.
Click here for sponsorship information. 

]]>
https://ibio.org/the-2019-icon-awards-are-tomorrow/feed/ 0
What GEN Missed in their TOP 10 US Biopharma Clusters Report https://ibio.org/what-gen-missed-in-their-top-10-us-biopharma-clusters/ https://ibio.org/what-gen-missed-in-their-top-10-us-biopharma-clusters/#respond Wed, 25 Sep 2019 12:13:24 +0000 https://ibio.org/?p=4303 Yesterday Genetic Engineering & Biotechnology News released their annual Top 10 U.S. Biopharma ClustersTop 10 U.S. Biopharma Clusters report. While the ranking showed growth in the Chicago region (we moved up one spot, from 10th to 9th), the report missed a lot of what is happening in our community.

First and foremost, iBIO applauded the 5 year extension of the R&D Tax Credit Governor Pritzker signed on August 2nd R&D Tax Credit Governor Pritzker signed on August 2nd. The extension of the credit is an important step to our ultimate goal of a permanent extension.

There was no mention of the Discovery Partners Institute (DPI) and the state’s $500 million commitment to growing public-private research partnerships. It was announced on August 30th that DPI earned state approval for the next 5 years August 30th that DPI earned state approval for the next 5 years.

While the report does mention the growth in lab space development, citing Sterling Bay and Northwestern University. The report missed a number of other developments in the community:

  • Rosalind Franklin University’s Science and Innovation Research Park in North Chicago 100,000 sqf of newly constructed lab space, opening this fall.
  • 146,000 sqf of space currently being renovated at the Illinois Science + Technology Park in Skokie
  • University of Chicago’s Polsky Center expansion is expected to add an additional 280,000 sqf of office and lab space in Hyde Park by 2022.
  • Burnham Lakefront Mega Development Project
  • Under investment, there was no mention of Deerfield Management’s $65 million partnership with Northwestern and their $65 million partnership with UIC to foster the development of new therapeutics.

And finally, this report just focuses on the pharmaceutical and biopharma industry. One of our community’s biggest strengths is that we are diverse and have major initiatives and companies in the medtech, health IT, and food & nutrition industries.

There are a number of “life sciences metropolitan ranking” reports released every year. It is a great marketing piece, and I am sure it drives a lot of traffic. And on a positive note, it does create a conversation around what we need to do to improve our community (read iBIO’s State of the Industry and Economic Blueprint). But take it for what it is, entertainment, and not an economic indicator of the community’s health.

What did I miss in my list? Let me know.

]]>
https://ibio.org/what-gen-missed-in-their-top-10-us-biopharma-clusters/feed/ 0
iBIO Joins Broad Coalition of Stakeholders Urge Congress to Permanently Repeal the Medical Device Tax https://ibio.org/ibio-joins-broad-coalition-of-stakeholders-urge-congress-to-permanently-repeal-the-medical-device-tax/ https://ibio.org/ibio-joins-broad-coalition-of-stakeholders-urge-congress-to-permanently-repeal-the-medical-device-tax/#respond Wed, 25 Sep 2019 11:08:47 +0000 https://ibio.org/?p=4299 iBIO along with The Advanced Medical Technology Association (AdvaMed), the Medical Device Manufacturers Association (MDMA), the Medical Imaging & Technology Alliance (MITA) and a broad coalition of medical innovators, physician inventors, patient groups, and others sent a letter to congressional leadership yesterday urging them to permanently repeal the medical device excise tax.

The medical device tax is a 2.3 percent levy on the sale of nearly every medical device sold in the country—from pacemakers and stents to MRI machines and CT scanners. The tax has previously been suspended by Congress twice, but absent Congressional action the most recent suspension will expire on January 1, 2020– a reality which threatens to once again undermine jobs, patients, and important breakthroughs in medical innovation.

Illinois is home to over 550 medical device companies, directly employing 13,000 Illinois workers. With $5.7 billion in economic output, the medical device industry is an important driver for the Illinois economy.

Despite the suspension of the tax, the medical device tax still has an adverse impact on R&D investment and job creation. For an industry that is built on constant innovation R&D spending has dropped in recent years, declining to 4.7% in 2013–17 from an average of 15.5% in 2000–07. (EY Pulse of the Industry 2018).

In all, over 600 signatures were on the letter urging lawmakers to repeal this economically harmful and innovation stifling tax. You can read the letter to congress here.

]]>
https://ibio.org/ibio-joins-broad-coalition-of-stakeholders-urge-congress-to-permanently-repeal-the-medical-device-tax/feed/ 0
ICON Awards and Halo Awards: Celebrating Illinois Scientists https://ibio.org/icon-awards-and-halo-awards-celebrating-illinois-scientists/ https://ibio.org/icon-awards-and-halo-awards-celebrating-illinois-scientists/#respond Mon, 23 Sep 2019 10:54:51 +0000 https://ibio.org/?p=4280

Don’t miss these great events celebrating researchers and innovation in Illinois.

Innovation is critical to the life sciences industry in Illinois, because innovation in the life sciences industry extend lives, improve quality of life and rive value to patients and the healthcare system as a whole.

With more than $2.5 billion in annual academic R&D, Illinois is home to some of the top researchers in the world who are fueling economic growth and job creation in the state.

Join our community in celebrating our scientific leaders at these two great events:

 

ICON Awards Reception – September 26, 2019 @ Chicago Botanic Garden

The iCON Awards celebrate the accomplishments of outstanding innovators and leaders whose work provides the basis for life sciences developments worldwide. Click here to register.

 

Halo Awards – October 12, 2019 @ Museum of Science & Industry

The Halo Awards is a first-of-its-kind Grammy-style event celebrating scientists for their tireless pursuit of cures and treatments that help people live better lives. This is not your typical award show. Use the code iBIOVIP to save on your registration. Click here to register.
]]>
https://ibio.org/icon-awards-and-halo-awards-celebrating-illinois-scientists/feed/ 0